What we can learn from FDA inspections since the QMSR
What FDA cites under the QMSR
This page helps medical device quality teams prepare for an FDA inspection. It shows what FDA cites under the Quality Management System Regulation (QMSR), FDA's own examples for an “official action indicated” (OAI) classification, and what to have ready for your CAPA system.
Since 2 February 2026, the QMSR (21 CFR Part 820) incorporates ISO 13485:2016 by reference. So FDA cites ISO 13485 clauses directly. Other citations come from requirements kept in Part 820, for example 820.35 (control of records), or from other FDA regulations, such as medical device reporting (Part 803) and unique device identification (Parts 801 and 830).
A Form 483 lists what the FDA investigator observed during the inspection.
The 1-minute version
Risk management and corrective action are the most cited requirements. Clause 7.1, mostly risk management, is in 31% of the Form 483s. Corrective action is in 26%, complaint handling in 25%. Counted across all ISO 13485 clauses, 41% of the Form 483s cite risk: more than any single requirement.
FDA also cites its own rules, not only ISO 13485. Medical device reporting (21 CFR 803) is in 13% of the Form 483s, UDI (21 CFR 801 Subpart B and 830) in 11%. ISO 13485 also has requirements on both topics, if regulations require them (clauses 8.2.3 and 7.5.8).
FDA checks how you corrected your last Form 483. FDA's inspection program tells investigators to check this. Repeat deficiencies are one of FDA's examples for an OAI.
FDA can now inspect more of your records. Under the old Quality System Regulation (QS Regulation), internal audit reports, management review records and supplier quality audit reports were exempt from FDA inspection. Under the QMSR, all three are subject to FDA inspection.
FDA quality system inspections of medical device sites that ended between 2 February and 20 October 2026
404
Of these, inspections with published Form 483 citations
21
Inspections classified "official action indicated" (OAI) so far
10
Warning letters to sites last inspected on or after 2 February 2026 (the date the QMSR started)
The most cited findings, in FDA's words
Each row is one finding: FDA's standard short text for an observation. The number is how many of the 404 Form 483s include it. The chart shows only findings in 5% or more of them.
Most cited findings: number of Form 483s
Rank
Finding (FDA short text)
Form 483s
1
7.1 · Product realization risk management processes not documentedShow FDA's long text
Most common FDA long text (53 of 66): One or more processes for risk management in product realization have not been adequately documented.
6616.3%
2
8.5.2 · Corrective action procedures not documentedShow FDA's long text
4.1.2 · Risk-based approach not applied to QMS processesShow FDA's long text
Most common FDA long text (28 of 45): A risk-based approach to the control of the appropriate processes needed for the quality management system has not been adequately applied.
4511.1%
4
8.2.2 · Complaint handling procedures not documentedShow FDA's long text
Most common FDA long text (30 of 39): Procedures for timely complaint handling have not been adequately documented.
399.7%
5
21 CFR 803.17 · Lack of Written MDR ProceduresShow FDA's long text
Most common FDA long text (12 of 37): Written MDR procedures have not been developed.
379.2%
5
7.1 · Records of risk management activities in product realization not maintainedShow FDA's long text
Most common FDA long text (20 of 37): Records of risk management activities in product realization were not adequately maintained.
379.2%
7
8.5.2 · Corrective action not takenShow FDA's long text
Most common FDA long text (26 of 35): Corrective action was not adequately taken to eliminate the cause of nonconformities in order to prevent recurrence.
358.7%
8
8.2.2 · Complaint handling procedures lack required elementsShow FDA's long text
FDA uses 20 different texts here.
286.9%
9
7.5.6 · Process for production and service provision not validatedShow FDA's long text
Most common FDA long text (14 of 26): Processes for production and service provision where the resulting output cannot be, or is not, verified by subsequent monitoring or measurement were not validated.
266.4%
10
8.2.2 · Complaint handling records not maintainedShow FDA's long text
Most common FDA long text (22 of 25): Complaint handling records were not adequately maintained.
256.2%
11
8.3.1 · Procedure for nonconforming product not documentedShow FDA's long text
Most common FDA long text (15 of 24): Procedures to define the controls and related responsibilities and authorities for the identification, documentation, segregation, evaluation, and disposition of nonconforming product were not adequately documented.
245.9%
12
7.4.1 · Procedures for purchasing process not documentedShow FDA's long text
Most common FDA long text (15 of 23): Procedures to ensure that purchased product conforms to specified purchasing information have not been adequately documented.
235.7%
13
4.1.1 · QMS not documented and maintained adequatelyShow FDA's long text
Most common FDA long text (14 of 22): The quality management system was not documented in accordance with applicable regulatory requirements.
225.4%
Per finding, not per requirement. Many requirements have several findings, so they are split over several rows. Risk management under 7.1 has two rows: 66 + 37 = 103 Form 483s. 7.1 as a whole is in 125 Form 483s (31%). Design changes (7.3.9) are in 40 Form 483s, but no single design change finding reaches 5%, so it has no row. For counts per requirement, see the 10 most cited requirements.
How the 769 inspections ended
No action indicated (NAI)
34144%
Voluntary action indicated (VAI)
40753%
Official action indicated (OAI)
213%
FDA classifies OAI cases months after the inspection, so the number of OAI inspections can still grow.
Since 2 February 2026, FDA inspects device makers according to its Compliance Program 7382.850. It sorts the QMS into six areas and adds four other FDA requirements. Every ISO 13485 clause belongs to one or two areas.
Source: FDA Compliance Program 7382.850, Part III – Inspectional, Diagram 1: FDA Medical Device Risk-Based Inspections.
The chart below shows the findings by area.
Form 483s with at least one finding in the area (of 404)
Management OversightIn 17 of the 20 OAI Form 483s
23458%
Measurement, Analysis and ImprovementIn 18 of the 20 OAI Form 483s
23257%
Change ControlIn 16 of the 20 OAI Form 483s
19047%
Production and Service ProvisionIn 12 of the 20 OAI Form 483s
14235%
Outsourcing and PurchasingIn 13 of the 20 OAI Form 483s
13533%
Design and DevelopmentIn 14 of the 20 OAI Form 483s
11528%
Medical device reporting (21 CFR 803)In 6 of the 20 OAI Form 483s
5213%
UDI (21 CFR 801 Subpart B and 830)In 6 of the 20 OAI Form 483s
4611%
Corrections and removals (21 CFR 806)In 2 of the 20 OAI Form 483s
51%
Tracking (21 CFR 821)No citations since 2 February 2026
00%
A Form 483 counts once in every area it touches, so the areas add up to more than 404. Some clauses are in two areas, for example 7.3.9 (design changes). 20 OAI Form 483s: FDA classified 21 inspections OAI, but published no citations for one of them.
Limits: the area of each clause is FDA's; the counting is mine (How I counted).
Inspection prep checklist: what this means for CAPA
I reviewed FDA's findings to assess what they might mean for your CAPA system. I identified five key areas you need to check to prepare for your next FDA inspection. Where possible, I listed what FDA found at other companies. Where QMSR-era examples are few, I also used Form 483s that FDA published from 2020 to 2024, under the old regulation.
1Your last Form 483if you had oneFDA checks how you corrected it. Repeat deficiencies are one of FDA's OAI examples.
All areas
Have ready, for each observation of your last Form 483
A problem statement that links back to FDA's observation.
Corrections and other initial actions, including their verification.
How deep the investigation went, your investigation approach, and how you separated causes from contributing factors.
As part of the CAPA scope: which other products, processes and records you checked.FDA found: FDA asked for a retrospective review in the letters to Linemaster and Nipro.
If affected product is already in the field: whether a recall was needed, and if not, why not.FDA found: Nipro: no plan for lots already released.
Corrective and/or preventive action, including their associated negative effect checks.
If procedures were changed as part of the action plan: evidence, beyond training records, that the training was effective.FDA found: Koven: training records alone were not enough.
Long-term evidence that the corrective action worked.FDA found: Nipro: nonconformities recurred after CAPAs were completed. A published Form 483 (2020): two observations marked “a repeat observation from the previous inspection” (2018), one on complaint investigation, one on the sample size of design verification tests.
How risk management was used to decide the depth of the investigation and the thoroughness of the actions.
Timelines: when each action was actually closed, compared with what you told FDA in your response.
2Corrective action8.5.2In 26% of the Form 483s (8.5.2). In 4 of the 7 warning letters.
FDA's inspection area: Measurement, Analysis and Improvement
Have ready
A CAPA procedure that covers at least the six parts FDA names (table below).
Risk-based criteria for when an issue needs a CAPA, and when an alternative like correction-only is enough.FDA found: O.N. Diagnostics: no clear rule for when an alternative response ("ticket") may be used instead of a CAPA. FDA: the procedure “now lacks clarity for when it is necessary to open a corrective action, based on risk”.
Changes to these criteria evaluated for their impact before they are implemented.FDA found: O.N. Diagnostics: revision 11 was to “narrow the CAPA triggers and place more emphasis on systemic or recurring issues”. FDA: “the impact of these changes was not evaluated prior to implementation”.
CAPA records with no blank fields: root cause, actions, effectiveness check.FDA found: Pensar: blank fields in 5 of 5 records. A published Form 483 (2020): 8 of 12 CAPAs inadequate.
CAPAs closed on time, or a written reason for each extension.FDA found: Nipro: “undue delay”. O.N. Diagnostics: procedural updates from four other CAPAs not made “for over a year and a half”. A published Form 483 (2020): extensions without a reason.
Effectiveness checks that show the problem did not happen again.FDA found: Nipro: nonconformities recurred after CAPAs were completed.
For each effectiveness check: a plan with the method and the acceptance criteria.FDA found: O.N. Diagnostics: “verification of implementation, but not of effectiveness”. No plan to verify effectiveness, “only a yes / no checkbox”.
Pre-CAPA requests, issue trackers and supplier corrective action requests: a decision on each entry, and an investigation where needed.FDA found: Published Form 483s: a CAPA request closed without a formal CAPA (2021); issue trackers open since 2007 (2020). Linemaster: a supplier corrective action request from a customer was not investigated. The response shows “Root Cause [BLANK]”. O.N. Diagnostics: a software issue known “three times over three years”; its CAPA was opened “the day before our inspection began”, unsigned and with no corrective actions identified.
CAPAs that check other products with the same part or process.FDA found: A published Form 483 (2021): one device family checked, others with the same foam not.
Corrective action procedures: the parts FDA names
Parts of the procedure that the FDA long text names (63 citations; one citation can name several parts):
Reviewing the effectiveness of corrective action taken
47
Planning and documenting action needed and implementing such action
30
Evaluating the need for action to ensure that nonconformities do not recur
28
Verifying that the corrective action does not adversely affect the ability to meet applicable regulatory requirements or the safety and performance of the medical device
28
Determining the causes of nonconformities
22
Reviewing nonconformities
19
All six parts named in one citation
9
In the data: FDA's text names the effectiveness review in 47 of the 63 citations “Corrective action procedures not documented”.
3Nonconforming product8.3In 15% of the Form 483s (8.3). In 2 of the 7 warning letters.
FDA's inspection area: Measurement, Analysis and Improvement
Have ready
A procedure for identification, documentation, segregation, evaluation and disposition of nonconforming product.
A record for every nonconformance and out-of-specification result, with a documented decision on whether an investigation is needed.FDA found: Nipro: 13 out-of-specification results without investigation.
Evidence that no product out of specification was released, or a concession with a justification and approval.FDA found: Nipro: “retesting of retain samples is not an appropriate justification”.
Rework done to documented instructions, and recorded.FDA found: Linemaster: rework not documented.
Nonconformity trends, and a rule for when a trend opens a CAPA.
4Sources that feed NC and CAPA8.2.2, 8.4, 7.6, 8.2.4, 5.6Inadequate data analysis that results in no investigation or corrective action can lead to an OAI.
FDA's inspection areas: Measurement, Analysis and Improvement + Management Oversight + Production and Service Provision
Note: Under the old Quality System Regulation (QS Regulation), internal audit reports, management review records and supplier quality audit reports were exempt from FDA inspection. Under the QMSR, all three are subject to FDA inspection (QMSR final rule, Federal Register, 2024).
Have ready
Returns, service records and support tickets checked to decide whether they are complaints, and the complaints handled in your complaint process.FDA found: Koven: 13 of 29 return forms reported failures but were not handled as complaints. The same with service records and support tickets in published Form 483s (2020, 2022).
For every complaint, a documented decision on the need for a correction or corrective action. Complaint trends with rates, and a rule for when a trend opens a CAPA.FDA found: A published Form 483 (2020): 39 confirmed over- or under-infusion complaints, with no documentation of why corrective action was not needed. FDA's texts name “Determining the need to initiate corrections or corrective actions” in 11 of the 28 citations “Complaint handling procedures lack required elements”. A published Form 483 (2024): 4,014 complaints not analyzed for trends.
Data analysis that includes suppliers, and supplier problems that lead to a supplier corrective action request or a CAPA.FDA found: A published Form 483 (2021): monitoring showed “no issues” while the wrong foam was supplied.
For instruments found out of calibration: an assessment of the earlier results and of the product measured with them, and the decision on a nonconformity or CAPA.FDA found: Nipro: an instrument used for product release never calibrated.
An internal audit program, the reports, and for each finding the corrections and corrective actions, taken without undue delay.
Management review records that show decisions and actions on known quality problems, not only discussion.FDA found: A published Form 483 (2021): a problem discussed at every management review, no further action for over a year.
5What your CAPAs should trigger7.1, 7.3.9, 7.5.6, 21 CFR 806Changes not evaluated for risk and impact before implementation can lead to an OAI.
FDA's inspection areas: Management Oversight + Change Control + Corrections and removals (21 CFR 806)
Have ready
Evidence that risk management files are updated after CAPAs, complaints, trends, recalls, management reviews and postmarket surveillance.FDA found: Nipro: not updated since 2020, despite a Class I recall.
For every field action (correction or removal): the causes behind it, the CAPAs implemented and verified, the update of the risk management file, and the decision on reporting it to FDA (21 CFR 806).FDA found: Pensar: software updates at customer sites that were a correction. A published Form 483 (2020): a parts replacement program, linked to a CAPA investigation of 2011, used as a field correction outside the corrections and removals process and not reported to FDA.
Where a CAPA plan includes a design or process change: evidence that change control and, where needed, revalidation were triggered and done before the change was implemented.
Latest warning letters
5 Nov 2026MODERN MEDICAL SUPPLIES LLCNo link yet
27 Oct 2026Orion Medical Solutions, LLCNo link yet
14 Oct 2026Emerge Technologies IncNo link yet
7 Oct 2026Olympus Medical Systems Corporation (7 sites)FDA letter
FDA's 10 most cited ISO 13485 clauses and 21 CFR sections, with all findings under each counted together.
Each row is one requirement as FDA cites it: an ISO 13485 clause or a 21 CFR section. The number is how many of the 404 Form 483s cite it, with any of its findings.
The 10 most cited requirements: share of the 404 Form 483s
#
Requirement
Form 483s
Share
1
7.1 Planning of product realization
125
31%
2
8.5.2 Corrective action
106
26%
3
8.2.2 Complaint handling
100
25%
4
7.4.1 Purchasing process
81
20%
5
7.5.6 Validation of processes for production and service provision
61
15%
6
8.3.1 Control of nonconforming product (general)
49
12%
7
4.1.2 General requirements (risk-based approach)
45
11%
8
7.3.9 Control of design and development changes
40
10%
9
4.1.5 General requirements (outsourced processes)
38
9%
10
21 CFR 803.17 (written MDR procedures)
37
9%
Per requirement, all findings together. 7.1 is titled “Planning of product realization”, but it also contains the requirements for risk management in product realization. Of its 125 Form 483s, 103 are about risk management. Sub-clauses are separate rows, for example 4.1.2 and 4.1.5. Requirements with the same number share a rank. 21 CFR 803.17 (written MDR procedures) is counted as FDA publishes it: 37 Form 483s cite 803.17 itself. With its sub-paragraphs (803.17(a)(1), (a)(2), (a)(3), (b)(1), (b)(2)) it would be 43 Form 483s (10.6%), rank 8.
Device warning letters since 2 February 2026
32 letters since 2 February 2026. 10 went to sites last inspected under the QMSR; for these, what FDA cited.
FDA's compliance-action data lists 32 warning letters about medical devices from 2 February to 5 November 2026. For each site, I looked up its last FDA inspection before the letter date. 10 letters went to sites last inspected on or after 2 February 2026, the date the QMSR started. For these, the table shows what FDA cited in that Form 483. For 2 of them, the inspection is not in FDA's inspection data yet. I took it from the letter, and the table shows what the letter cites.
The data shows that FDA issued a letter, not what the letter says, and not which inspection it is based on. FDA's data is not complete. At least one device warning letter that FDA published (dated 22 April 2026) is not in the data. The date in the data can differ from the date on the letter by a few days. For Orion Medical Solutions (27 October 2026), FDA's data has no inspection, and FDA has not posted the letter yet.
Findings and OAI classifications
FDA's own examples for an OAI classification, in FDA's words.
FDA Compliance Program 7382.850
FDA's own examples for an OAI classification
FDA's text before the examples: “Overall inspectional findings reveal serious, systemic, and/or repeat deviations from the regulation where there is evidence of an adverse impact from a failure, or other factors that have or may result in significant risk to patients and/or users.”
(a) QMS failure
“A failure to establish, implement, and/or maintain one or more element(s) of the QMS areas and/or OAFRs. …”
(b) Nonconforming product distributed
“Distribution of nonconforming product(s) that have caused, or may result in, injury or death without effective mitigation, and/or adequate corrective actions by the manufacturer.”
(c) Risk management failure
“Failure to establish, implement, and/or maintain one or more processes for risk management in product realization.”
(d) Monitoring and improvement failure
“Failure to monitor, measure, analyze, and improve processes that have demonstrated adverse impact to the finished product and/or to patient safety.”
(e) Data analysis failure
“Failure to adequately analyze data, and/or failure to utilize current risk information that results in a decision not to proceed with formal investigations and/or corrective actions, leading to unmitigated adverse health consequences or nonconformities. …”
(f) Repeat deficiencies
“Failure to adequately correct the same or similar significant deficiencies from previous inspections(s).”
(g) Feedback loop failure
“Information gathered through the feedback process and/or postmarket surveillance is not used as potential input(s) into risk management for monitoring and maintaining the product realization or improvement processes.”
(h) Design control failure
“Failure to control the design and development of product, including not adequately evaluating changes for risk and impact on product(s) prior to implementation.”
(i) Process control failure
“Failure to ensure processes, including changes, are adequately monitored, controlled and/or evaluated for risk and impact on products prior to implementation.”
Note: changes without a submission
“If changes made by a manufacturer appear to warrant the need for new clearance (510(k)) or approval (PMA) and no submissions were made, the inspection should result in an initial OAI classification …”
All nine examples in FDA's Compliance Program 7382.850, Part V (“not all inclusive”), in FDA's order, and FDA's note on changes. The short labels are mine. OAFRs: FDA's four other requirements (medical device reporting, tracking, corrections and removals, UDI).
About the data
What a Form 483 is, what NAI, VAI and OAI mean, how to read the numbers, and how I counted.
A Form 483 lists what the FDA investigator observed during the inspection. It is not a final FDA decision.
FDA classifies every inspection. NAI (no action indicated): FDA found no objectionable conditions, or none that need further action. VAI (voluntary action indicated): FDA found objectionable conditions but does not plan regulatory action. OAI (official action indicated): FDA recommends regulatory or administrative action, for example a warning letter.
A citation is one requirement that FDA cited in a Form 483. FDA publishes each citation as standard wording: a short text (the finding) and a long text. The facts of each case are not in this data. The full Form 483 can be requested from FDA.
Percentages are shares of the 404 Form 483s, unless a line says otherwise. A Form 483 counts once per requirement or finding, even if FDA cited it twice in it.
Not every inspection with findings has published citations: 28 inspections classified VAI or OAI have none; 18 of them were at sites in Asia. 358 of the 404 Form 483s (89%) are from sites in the United States. So the findings show mainly what FDA cites at US sites.
FDA keeps adding inspections, citations and letters, also for past months. So the numbers on this page change from week to week. The dates under “Page updated” show which data this page uses.
Sources: FDA Data Dashboard (inspections, inspection citations and compliance actions, product type devices), exported on 16 November 2026. Letter texts: FDA's website.
This page summarizes public FDA data. Company names are as FDA publishes them. It is not legal advice.
How I counted
Which inspections: inspections with the project area "Compliance: Devices" (quality system inspections) that ended between 2 February 2026 and the date under "Inspections up to". Not included: inspections of clinical studies (Bioresearch Monitoring), postmarket and radiation-only inspections.
FDA's device citation export also contains citations from other inspection types: clinical studies, postmarket and radiation. They are left out.
Outcome: FDA's classification of the inspection. If FDA classified the project areas of one inspection differently, I use the most serious one (OAI before VAI before NAI).
Risk management in 7.1 (the 1-minute version): FDA's short text is about risk management in 103 of the 125 Form 483s that cite 7.1 (“Product realization risk management processes not documented” or “Records of risk management activities in product realization not maintained”).
Risk: an ISO 13485 citation counts as a citation about risk if its FDA short or long text contains the word "risk".
Warning letters: one letter can name several sites (FEI numbers). I linked each site to its most recent FDA inspection in the data before the letter date. If FDA has posted the letter and it names a later inspection that is not in the data, I use the letter's inspection (2 letters: O.N. Diagnostics and Nihon Kohden Digital Health Solutions).
FDA's areas: Attachment A of Compliance Program 7382.850 assigns each ISO 13485 clause to one or two areas. 21 CFR 820.35(a) (complaint records) counts in Measurement, Analysis and Improvement, the rest of 820.35 and 21 CFR 820.45 (labeling) in Production and Service Provision. For UDI, I count 21 CFR 830 and 21 CFR 801 Subpart B (the UDI on the label). Attachment A names 21 CFR 830, 820.45 and 820.10(b)(1). Eight citations of old QS Regulation sections after 2 February are counted in the area of their topic; 1 citation (registration) is in no area.
Checklist facts: the 7 warning letters after QMSR inspections that FDA has posted, and 5 device Form 483s that FDA has published (2020, 2021, 2022 and 2024, old QS Regulation). FDA publishes Form 483s because of meaningful public interest or repeated FOIA requests.
I count the numbers with a script. Before each update, a second method recounts the main numbers: inspections, Form 483s, citations, outcomes and the shares in the 1-minute version.
Questions about NC and CAPA for your own inspection?
The MedTech CAPA Journal goes to 500+ quality professionals, about twice a week. I write about what FDA's warning letters show in the context of your NCs and CAPAs, and how to avoid findings on them. Subscribe and I’ll send you the CAPA Stress Test toolkit as a welcome gift.